Travere Therapeutics’ (TVTX) “Outperform” Rating Reiterated at Wedbush
Wedbush restated their outperform rating on shares of Travere Therapeutics (NASDAQ:TVTX – Free Report) in a report published on Friday,Benzinga reports. They currently have a $30.00 price target on the stock. Several other equities analysts have also issued reports on TVTX. Cantor Fitzgerald restated an “overweight” rating on shares of Travere Therapeutics in a report […]
Wedbush restated their outperform rating on shares of Travere Therapeutics (NASDAQ:TVTX – Free Report) in a report published on Friday,Benzinga reports. They currently have a $30.00 price target on the stock. Several other equities analysts have also issued reports on TVTX. Cantor Fitzgerald restated an “overweight” rating on shares of Travere Therapeutics in a report […]
